ReviewFrontiers in oncology2025
The role of apelin in cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apelin aggravates inflammatory response and hepatic steatosis in alcohol-associated liver disease via ERK signaling pathway.Frontiers in pharmacology · 2026Article
- The Apelinergic System in Kidney Disease: Novel Perspectives.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apelin is widely expressed in the body. Apelin is secreted as a propeptide and is proteolytically cleaved into six main isoforms. As an adipokine, apelin has a cardio- and neuroprotective role and is involved in angiogenesis in healthy tissue. Recently, numerous roles of endothelial cell-derived apelin on cancer cells have been uncovered, including angiogenesis, cell proliferation, and cellular invasion. Studies have reported elevated apelin levels in tumor tissue of patients with cancer compared to healthy controls, highlighting its role in determining prognosis. Research suggests that inhibiting apelin reduces tumor invasiveness and angiogenesis and further mechanistic studies are required to realize the full potential of therapeutics targeting apelin in malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.